Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Therapy in Patients With Genetic Alterations in Non‐Small Cell Lung Cancer
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Tsunehiro Tanaka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Paclitaxel, Carboplatin, Lung Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taiho Pharmaceutical.
Abstract (Originalsprache)
Background
The IMpower150 trial demonstrated the efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel ( ABCP ) therapy in epidermal growth factor receptor ( EGFR )‐mutated non‐small cell lung cancer ( NSCLC ). However, its efficacy in patients with NSCLC harboring other genetic alterations in real‐world settings remains unclear. This study aimed to retrospectively evaluate the efficacy of ABCP therapy in patients with NSCLC harboring other genetic alterations.
Methods
We retrospectively analyzed 61 patients with advanced NSCLC (33 with EGFR mutations: EGFR group and 28 with other genetic alterations: other group) who received ABCP therapy between January 2019 and December 2023 at a single institution in Japan, and evaluated efficacy and toxicities.
Results
Most baseline characteristics were similar except treatment timing ( p < 0.001) in both groups. The median progression‐free survival ( PFS ) was 4.5 vs. 5.1 months ( p = 0.663), and the objective response rate ( ORR ) was 45.5% vs. 50.0% ( p = 0.77) between the EGFR and other groups. In multivariate analysis, PD ‐ L1 expression ≥ 50% was independently associated with longer PFS ( HR 0.23, p < 0.001). Grade ≥ 3 adverse events were manageable and occurred at similar rates (51.5% vs. 53.6%) between the EGFR and other groups, and discontinuation was low (9.8%). Subgroup analysis for patients with KRAS mutation ( n = 14) and anaplastic lymphoma kinase ( ALK ) fusion ( n = 6) showed trends consistent with the overall cohort.
Conclusions
ABCP therapy demonstrated efficacy and manageable toxicity in NSCLC patients in both groups. Notably, those with high PD ‐ L1 expression (≥ 50%) may derive greater PFS benefit. Further confirmation in larger prospective trials is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan.
ORCID-Profile: Tsunehiro Tanaka, Takako Inoue
Förderung
- Taiho Pharmaceutical
Zitieren
APA
Tanaka, T., Tamiya, M., Miyazaki, A., Komura, K., Futamura, S., Kawamura, T., Kunimasa, K., Inoue, T., & Nishino, K. (2025). Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Therapy in Patients With Genetic Alterations in Non‐Small Cell Lung Cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70162
Vancouver
Tanaka T, Tamiya M, Miyazaki A, Komura K, Futamura S, Kawamura T, et al. Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Therapy in Patients With Genetic Alterations in Non‐Small Cell Lung Cancer. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70162
BibTeX
@article{Tanaka2025,
author = {Tanaka, Tsunehiro and Tamiya, Motohiro and Miyazaki, Akito and Komura, Kiyohide and Futamura, Shun and Kawamura, Takahisa and Kunimasa, Kei and Inoue, Takako and Nishino, Kazumi},
title = {Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Therapy in Patients With Genetic Alterations in Non‐Small Cell Lung Cancer},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70162}
}
EUVIMED